Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, Mares JE, Abdalla EK, Fleming JB, Vauthey JN, Rashid A, Evans DB. One hundred years after carcinoid: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008;26(18):3063-72. https://doi.org/10.1200/JCO.2007.15.4377.

Pavel M, Baudin E, Couvelard A, Krenning E, Öberg K, Steinmüller T, Anlauf M, Wiedenmann B, Salazar R. Barcelona Consensus Conference participants. ENETS Consensus Guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary. Neuroendocrinology. 2012;95(2):157 – 76. https://doi.org/10.1159/000335597.

Basturk O, Tang L, Hruban RH, Adsay V, Yang Z, Krasinskas AM, Vakiani E, La Rosa S, Jang KT, Frankel WL, Liu X, Zhang L, Giordano TJ, Bellizzi AM, Chen JH, Shi C, Allen P, Reidy DL, Wolfgang CL, Saka B, Rezaee N, Deshpande V, Klimstra DS. Poorly differentiated neuroendocrine carcinomas of the pancreas: a clinicopathologic analysis of 44 cases. Am J Surg Pathol. 2014;38(4):437–47. https://doi.org/10.1097/PAS.0000000000000169.

Gangi A, Howe JR. The Landmark Series: neuroendocrine tumor liver metastases. Ann Surg Oncol. 2020;27(9):3270–80. https://doi.org/10.1245/s10434-020-08787-x.

Chiti A, Fanti S, Savelli G, Romeo A, Bellanova B, Rodari M, van Graafeiland BJ, Monetti N, Bombardieri E. Comparison of somatostatin receptor imaging, computed tomography and ultrasound in the clinical management of neuroendocrine gastro-entero-pancreatic tumours. Eur J Nucl Med. 1998;25(10):1396 – 403. https://doi.org/10.1007/s002590050314.

Modlin IM, Kidd M, Latich I, Zikusoka MN, Shapiro MD. Current status of gastrointestinal carcinoids. Gastroenterology. 2005;128(6):1717-51. https://doi.org/10.1053/j.gastro.2005.03.038.

Levy S, Verbeek WHM, Eskens FALM, van den Berg JG, de Groot DJA, van Leerdam ME, Tesselaar MET. First-line everolimus and cisplatin in patients with advanced extrapulmonary neuroendocrine carcinoma: a nationwide phase 2 single-arm clinical trial. Ther Adv Med Oncol. 2022;14:17588359221077088. https://doi.org/10.1177/17588359221077088.

Myrehaug S, Chan DL, Rodriguez-Freixinos V, Chung H, Hallet J, Law C, Patel C, Milot L, Hudson J, Chen H, Singh S. A pilot study of everolimus and radiation for neuroendocrine liver metastases. Endocr Relat Cancer. 2021;28(8):541–548. https://doi.org/10.1530/ERC-21-0030.

Vaghaiwalla T, Memeh K, Liao C-Y, Keutgen XM. Metastatic well-differentiated pancreatic neuroendocrine tumors to the liver: a narrative review of systemic and Surgical Management. J Pancreatology. 2021;4(2):82–9. https://doi.org/10.1097/jp9.0000000000000068.

Article  Google Scholar 

Carrasco CH, Charnsangavej C, Ajani J, Samaan NA, Richli W, Wallace S. The carcinoid syndrome: palliation by hepatic artery embolization. AJR Am J Roentgenol. 1986;147(1):149 – 54. https://doi.org/10.2214/ajr.147.1.149.

Egger ME, Armstrong E, Martin RC 2nd, Scoggins CR, Philips P, Shah M, Konda B, Dillhoff M, Pawlik TM, Cloyd JM. Transarterial Chemoembolization vs Radioembolization for Neuroendocrine Liver Metastases: A Multi-Institutional Analysis. J Am Coll Surg. 2020;230(4):363–370. doi: 10.1016/j.jamcollsurg.2019.12.026.

Norlén O, Stålberg P, Öberg K, Eriksson J, Hedberg J, Hessman O, Janson ET, Hellman P, Åkerström G. Long-term results of surgery for small intestinal neuroendocrine tumors at a tertiary referral center. World J Surg. 2012;36(6):1419-31. https://doi.org/10.1007/s00268-011-1296-z.

Modlin IM, Lye KD, Kidd M. A 5-decade analysis of 13,715 carcinoid tumors. Cancer. 2003;97(4):934 – 59. https://doi.org/10.1002/cncr.11105.

Rindi G, D’Adda T, Froio E, Fellegara G, Bordi C. Prognostic factors in gastrointestinal endocrine tumors. Endocr Pathol. 2007 July;18(3):145–9. https://doi.org/10.1007/s12022-007-0020-x.

Kraft A, Croitoru A, Moldovan C, Lupescu I, Tomescu D, Purnichescu-Purtan R, Herlea V, Popescu I, Botea F. Is long-term survival in metastases from neuroendocrine neoplasms improved by Liver Resection? Med (Kaunas). 2021;58(1):22. https://doi.org/10.3390/medicina58010022.

Concors SJ, Maxwell JE. Neuroendocrine hepatic metastatic disease: the surgeon’s perspective. Abdom Radiol (NY). 2022;47(12):4073–80. https://doi.org/10.1007/s00261-022-03515-3.

Ziv E, Rice SL, Filtes J, Yarmohammadi H, Boas FE, Erinjeri JP, Petre EN, Brody LA, Brown KT, Covey AM, Getrajdman GI, Maybody M, Raj N, Sofocleous CT, Solomon SB, Reidy-Lagunes D. DAXX Mutation Status of embolization-treated neuroendocrine tumors predicts shorter time to hepatic progression. J Vasc Interv Radiol. 2018;29(11):1519–26.

Kulke MH, Anthony LB, Bushnell DL, de Herder WW, Goldsmith SJ, Klimstra DS, Marx SJ, Pasieka JL, Pommier RF, Yao JC, Jensen RT, North American Neuroendocrine Tumor Society (NANETS). NANETS treatment guidelines: well-differentiated neuroendocrine tumors of the stomach and pancreas. Pancreas. 2010;39(6):735–52. https://doi.org/10.1097/MPA.0b013e3181ebb168.

Ronot M, Clift AK, Baum RP, Singh A, Kulkarni HR, Frilling A, Vilgrain V. Morphological and functional imaging for detecting and assessing the resectability of neuroendocrine liver metastases. Neuroendocrinology. 2018;106(1):74–88.

Gibril F, Jensen RT. Comparative analysis of diagnostic techniques for localization of gastrointestinal neuroendocrine tumors. Yale J Biol Med. 1997 Sep-Dec;70(5–6):509–22.

Chambers AJ, Pasieka JL, Dixon E, Rorstad O. Role of imaging in the preoperative staging of small bowel neuroendocrine tumors. J Am Coll Surg. 2010;211(5):620-7. doi: 10.1016/j.jamcollsurg.2010.07.016

Pisegna JR, Doppman JL, Norton JA, Metz DC, Jensen RT. Prospective comparative study of ability of MR imaging and other imaging modalities to localize tumors in patients with Zollinger-Ellison syndrome. Dig Dis Sci. 1993;38(7):1318–28. https://doi.org/10.1007/BF01296084.

Frucht H, Doppman JL, Norton JA, Miller DL, Dwyer AJ, Frank JA, Vinayek R, Maton PN, Jensen RT. Gastrinomas: comparison of MR imaging with CT, angiography, and US. Radiology. 1989;171(3):713-7. https://doi.org/10.1148/radiology.171.3.2655004.

Cwikła JB, Buscombe JR, Caplin ME, Watkinson AF, Walecki J, Gorczyca-Wiśniewska E, Hilson AJ. Diagnostic imaging of carcinoid metastases to the abdomen and pelvis. Med Sci Monit. 2004;10(Suppl 3):9–16.

Półtorak-Szymczak G, Budlewski T, Furmanek MI, Wierzba W, Sklinda K, Walecki J, Mruk B. Radiological Imaging of Gastro-Entero-Pancreatic Neuroendocrine Tumors. The review of current literature emphasizing the Diagnostic Value of Chosen Imaging methods. Front Oncol. 2021;11:670233. https://doi.org/10.3389/fonc.2021.670233.

Neri E, Bali MA, Ba-Ssalamah A, Boraschi P, Brancatelli G, Alves FC, Grazioli L, Helmberger T, Lee JM, Manfredi R, Martì-Bonmatì L, Matos C, Merkle EM, Op De Beeck B, Schima W, Skehan S, Vilgrain V, Zech C, Bartolozzi C. ESGAR consensus statement on liver MR imaging and clinical use of liver-specific contrast agents. Eur Radiol. 2016;26(4):921–31.

• Morin C, Drolet S, Daigle C, Deshaies I, Ouellet JF, Ball CG, Dixon E, Marceau J, Ouellet JB. Additional value of gadoxetic acid-enhanced MRI to conventional extracellular gadolinium-enhanced MRI for the surgical management of colorectal and neuroendocrine liver metastases. HPB (Oxford). 2020;22(5):710–5. https://doi.org/10.1016/j.hpb.2019.09.009. This articles highlights the benefit of contrast enhanced MRI for detection of NET liver metastases.

Tirumani SH, Jagannathan JP, Braschi-Amirfarzan M, Qin L, Balthazar P, Ramaiya NH, Shinagare AB. Value of hepatocellular phase imaging after intravenous gadoxetate disodium for assessing hepatic metastases from gastroenteropancreatic neuroendocrine tumors: comparison with other MRI pulse sequences and with extracellular agent. Abdom Radiol (NY). 2018;43(9):2329–2339. https://doi.org/10.1007/s00261-018-1496-1.

Muhi A, Ichikawa T, Motosugi U, Sou H, Nakajima H, Sano K, Sano M, Kato S, Kitamura T, Fatima Z, Fukushima K, Iino H, Mori Y, Fujii H, Araki T. Diagnosis of colorectal hepatic metastases: comparison of contrast-enhanced CT, contrast-enhanced US, superparamagnetic iron oxide-enhanced MRI, and gadoxetic acid-enhanced MRI. J Magn Reson Imaging. 2011;34(2):326 – 35. https://doi.org/10.1002/jmri.22613.

Yang J, Kan Y, Ge BH, Yuan L, Li C, Zhao W. Diagnostic role of Gallium-68 DOTATOC and Gallium-68 DOTATATE PET in patients with neuroendocrine tumors: a meta-analysis. Acta Radiol. 2014;55(4):389–98.

Antunes P, Ginj M, Zhang H, Waser B, Baum RP, Reubi JC, Maecke H. Are radiogallium-labelled DOTA-conjugated somatostatin analogues superior to those labelled with other radiometals? Eur J Nucl Med Mol Imaging. 2007;34(7):982 – 93. https://doi.org/10.1007/s00259-006-0317-x.

Jackson T, Darwish M, Cho E, Nagatomo K, Osman H, Jeyarajah DR. 68Ga-DOTATATE PET/CT compared to standard imaging in metastatic neuroendocrine tumors: a more sensitive test to detect liver metastasis? Abdom Radiol (NY). 2021;46(7):3179–3183. https://doi.org/10.1007/s00261-021-02990-4.

Zhang P, Yu J, Li J, Shen L, Li N, Zhu H, Zhai S, Zhang Y, Yang Z, Lu M. Clinical and Prognostic Value of PET/CT Imaging with combination of 68Ga-DOTATATE and 18F-FDG in Gastroenteropancreatic Neuroendocrine neoplasms. Contrast Media Mol Imaging. 2018;2018:2340389. https://doi.org/10.1155/2018/2340389.

Kayani I, Bomanji JB, Groves A, Conway G, Gacinovic S, Win T, Dickson J, Caplin M, Ell PJ. Functional imaging of neuroendocrine tumors with combined PET/CT using 68Ga-DOTATATE (DOTA-DPhe1,Tyr3-octreotate) and 18F-FDG. Cancer. 2008;112(11):2447-55. https://doi.org/10.1002/cncr.23469.

Abgral R, Leboulleux S, Déandreis D, Aupérin A, Lumbroso J, Dromain C, Duvillard P, Elias D, de Baere T, Guigay J, Ducreux M, Schlumberger M, Baudin E. Performance of (18)fluorodeoxyglucose-positron emission tomography and somatostatin receptor scintigraphy for high Ki67 (≥ 10%) well-differentiated endocrine carcinoma staging. J Clin Endocrinol Metab. 2011;96(3):665–71.

• Frilling A, Li J, Malamutmann E, Schmid KW, Bockisch A, Broelsch CE. Treatment of liver metastases from neuroendocrine tumours in relation to the extent of hepatic disease. Br J Surg. 2009;96(2):175 – 84. https://doi.org/10.1002/bjs.6468. This was the first article to delineate a classification for liver metastases to aid in determining when to consider liver surgery.

Mahuron KM, Singh G. Defining a new classification system for the Surgical Management of Neuroendocrine Tumor Liver metastases. J Clin Med. 2023;12(7):2456. https://doi.org/10.3390/jcm12072456.

• Schreckenbach T, Hübert H, Koch C, Bojunga J, Schnitzbauer AA, Bechstein WO, Holzer K. Surgical resection of neuroendocrine tumor liver metastases as part of multimodal treatment strategies: A propensity score matching analysis. Eur J Surg Oncol. 2019;45(5):808–815. doi: 10.1016/j.ejso.2018.12.022. This study demonstrates that surgical resection does not necessarily improve overall survival in patients with metastatic NET. Suggesting careful selection of whom to operate on is important to improve long term outcomes.

Norlén O, Stålberg P, Zedenius J, Hellman P. Outcome after resection and radiofrequency ablation of liver metastases from small intestinal neuroendocrine tumours. Br J Surg. 2013;100(11):1505-14. https://doi.org/10.1002/bjs.9262.

Inoue Y, Kagota S, Tsuchimoto Y, Ogura T, Asai A, Fukunishi S, Higuchi K, Uchiyama K. Laparoscopic liver resection for patients with cardiac disease. Contemp Oncol (Pozn). 2019;23(1):37–42. https://doi.org/10.5114/wo.2019.84109.

Juhlin CC, Zedenius J, Höög A. Metastatic neuroendocrine neoplasms of unknown primary: clues from Pathology Workup. Cancers (Basel). 2022;14(9):2210. https://doi.org/10.3390/cancers14092210.

Dohan A, El Fattach H, Barat M, Guerrache Y, Eveno C, Dautry R, Mulé S, Boudiaf M, Hoeffel C, Soyer P. Neuroendocrine tumors of the small bowel: evaluation with MR-enterography. Clin Imaging. 2016 May-Jun;40(3):541–7.

Frilling A, Sotiropoulos GC, Li J, Kornasiewicz O, Plöckinger U. Multimodal management of neuroendocrine liver metastases. HPB (Oxford). 2010;12(6):361–79. https://doi.org/10.1111/j.1477-2574.2010.00175.x.

Cloyd JM, Ejaz A, Konda B, Makary MS, Pawlik TM. Neuroendocrine liver metastases: a contemporary review of treatment strategies. Hepatobiliary Surg Nutr. 2020;9(4):440–51. https://doi.org/10.21037/hbsn.2020.04.02.

Fairweather M, Swanson R, Wang J, Brais LK, Dutton T, Kulke MH, Clancy TE. Management of neuroendocrine Tumor Liver metastases: long-term outcomes and prognostic factors from a large prospective database. Ann Surg Oncol. 2017;24(8):2319–25. https://doi.org/10.1245/s10434-017-5839-x.

Kaçmaz E, Heidsma CM, Besselink MGH, Dreijerink KMA, Klümpen HJ, van Nieveen EJM, Engelsman AF. Treatment of Liver metastases from Midgut Neuroendocrine tumours: a systematic review and Meta-analysis. J Clin Med. 2019;8(3):403. https://doi.org/10.3390/jcm8030403.

Gudmundsdottir H, Habermann EB, Vierkant RA, Starlinger P, Thiels CA, Warner SG, Smoot RL, Truty MJ, Kendrick ML, Halfdanarson TR, Nagorney DM, Cleary SP. Survival and symptomatic relief after Cytoreductive Hepatectomy for Neuroendocrine Tumor Liver metastases: long-term follow-up evaluation of more than 500 patients. Ann Surg Oncol. 2023;30(8):4840–51. https://doi.org/10.1245/s10434-023-13372-z.

Saxena A, Chua TC, Perera M, Chu F, Morris DL. Surgical resection of hepatic metastases from neuroendocrine neoplasms: a systematic review. Surg Oncol. 2012;21(3):e131–41. https://doi.org/10.1016/j.suronc.2012.05.001.

McEntee GP, Nagorney DM, Kvols LK, Moertel CG, Grant CS. Cytoreductive hepatic surgery for neuroendocrine tumors. Surgery. 1990;108(6):1091-6.

Sarmiento JM, Heywood G, Rubin J, Ilstrup DM, Nagorney DM, Que FG. Surgical treatment of neuroendocrine metastases to the liver: a plea for resection to increase survival. J Am Coll Surg. 2003;197(1):29–37. https://doi.org/10.1016/S1072-7515(03)00230-8.

Chambers AJ, Pasieka JL, Dixon E, Rorstad O. The palliative benefit of aggressive surgical intervention for both hepatic and mesenteric metastases from neuroendocrine tumors. Surgery. 2008;144(4):645 – 51; discussion 651-3. https://doi.org/10.1016/j.surg.2008.06.008.

Graff-Baker AN, Sauer DA, Pommier SJ, Pommier RF. Expanded criteria for carcinoid liver debulking: Maintaining survival and increasing the number of eligible patients. Surgery. 2014;156(6):1369-76; discussion 1376-7. https://doi.org/10.1016/j.surg.2014.08.009.

• Maxwell JE, Sherman SK, O’Dorisio TM, Bellizzi AM, Howe JR. Liver-directed surgery of neuroendocrine metastases: What is the optimal strategy? Surgery. 2016;159(1):320 – 33. https://doi.org/10.1016/j.surg.2015.05.040. This study demonstrated elegantly that using a lower threshold for considering liver resection may still be beneficial, rather than a debulking cut-off of > 90% being considered.

Scott AT, Breheny PJ, Keck KJ, Bellizzi AM, Dillon JS, O’Dorisio TM, Howe JR. Effective cytoreduction can be achieved in patients with numerous neuroendocrine tumor liver metastases (NETLMs). Surgery. 2019;165(1):166–75. https://doi.org/10.1016/j.surg.2018.04.070.

Boudreaux JP, Wang YZ, Diebold AE, Frey DJ, Anthony L, Uhlhorn AP, Ryan P, Woltering EA. A single institution’s experience with surgical cytoreduction of stage IV, well-differentiated, small bowel neuroendocrine tumors. J Am Coll Surg. 2014;218(4):837 – 44. doi: 10.1016/j.jamcollsurg.2013.12.035.

Kandil E, Noureldine SI, Koffron A, Yao L, Saggi B, Buell JF. Outcomes of laparoscopic and open resection for neuroendocrine liver metastases. Surgery. 2012;152(6):1225–31. https://doi.org/10.1016/j.surg.2012.08.027.

Mayo SC, de Jong MC, Pulitano C, Clary BM, Reddy SK, Gamblin TC, Celinksi SA, Kooby DA, Staley CA, Stokes JB, Chu CK, Ferrero A, Schulick RD, Choti MA, Mentha G, Strub J, Bauer TW, Adams RB, Aldrighetti L, Capussotti L, Pawlik TM. Surgical management of hepatic neuroendocrine tumor metastasis: results from an international multi-institutional analysis. Ann Surg Oncol. 2010;17(12):3129–36. https://doi.org/10.1245/s10434-010-1154-5.

Spolverato G, Bagante F, Aldrighetti L, Poultsides GA, Bauer TW, Fields RC, Maithel SK, Marques HP, Weiss M, Pawlik TM. Management and outcomes of patients with recurrent neuroendocrine liver metastasis after curative surgery: an international multi-institutional analysis. J Surg Oncol. 2017;116(3):298–306. https://doi.org/10.1002/jso.24670.

Elias D, Lasser P, Ducreux M, Duvillard P, Ouellet JF, Dromain C, Schlumberger M, Pocard M, Boige V, Miquel C, Baudin E. Liver resection (and associated extrahepatic resections) for metastatic well-differentiated endocrine tumors: a 15-year single center prospective study. Surgery. 2003;133(4):375 – 82. https://doi.org/10.1067/msy.2003.114.

Glazer ES, Tseng JF, Al-Refaie W, Solorzano CC, Liu P, Willborn KA, Abdalla EK, Vauthey JN, Curley SA. Long-term survival after surgical management of neuroendocrine hepatic metastases. HPB (Oxford). 2010;12(6):427–33. https://doi.org/10.1111/j.1477-2574.2010.00198.x.

Akyildiz HY, Mitchell J, Milas M, Siperstein A, Berber E. Laparoscopic radiofrequency thermal ablation of neuroendocrine hepatic metastases: long-term follow-up. Surgery. 2010;148(6):1288-93; discussion 1293. https://doi.org/10.1016/j.surg.2010.09.014.

Loffroy R, Favelier S, Chevallier O, Estivalet L, Genson PY, Pottecher P, Gehin S, Krausé D, Cercueil JP. Preoperative portal vein embolization in liver cancer: indications, techniques and outcomes. Quant Imaging Med Surg. 2015;5(5):730-9. https://doi.org/10.3978/j.issn.2223-4292.2015.10.04. Erratum in: Quant Imaging Med Surg. 2016;6(5):619–620.

Madoff DC, Gupta S, Ahrar K, Murthy R, Yao JC. Update on the management of neuroendocrine hepatic metastases. J Vasc Interv Radiol. 2006;17(8):1235-49; quiz 1250. https://doi.org/10.1097/01.RVI.0000232177.57950.71.

van Lienden KP, van den Esschert JW, de Graaf W, Bipat S, Lameris JS, van Gulik TM, van Delden OM. Portal vein embolization before liver resection: a systematic review. Cardiovasc Intervent Radiol. 2013;36(1):25–34. https://doi.org/10.1007/s00270-012-0440-y.

Abulkhir A, Limongelli P, Healey AJ, Damrah O, Tait P, Jackson J, Habib N, Jiao LR. Preoperative portal vein embolization for major liver resection: a meta-analysis. Ann Surg. 2008;247(1):49–57. https://doi.org/10.1097/SLA.0b013e31815f6e5b.

Rassam F, Olthof PB, van Lienden KP, Bennink RJ, Erdmann JI, Swijnenburg RJ, Busch OR, Besselink MG, van Gulik TM. Comparison of functional and volumetric increase of the future remnant liver and postoperative outcomes after portal vein embolization and complete or partial associating liver partition and portal vein ligation for staged hepatectomy (ALPPS). Ann Transl Med. 2020;8(7):436. https://doi.org/10.21037/atm.2020.03.191.

Bell RJ, Hakeem AR, Pandanaboyana S, Davidson BR, Prasad RK, Dasari BVM. Portal vein embolization versus dual vein embolization for management of the future liver remnant in patients undergoing major hepatectomy: meta-analysis. BJS open. 2022;6(6):zrac131. https://doi.org/10.1093/bjsopen/zrac131.

Article  PubMed  PubMed Central  Google Scholar 

Linecker M, Kambakamba P, Raptis DA, Malagó M, Ratti F, Aldrighetti L, Robles-Campos R, Lehwald-Tywuschik N, Knoefel WT, Balci D, Ardiles V, De Santibañes E, Truant S, Pruvot FR, Stavrou GA, Oldhafer KJ, Voskanyan S, Mahadevappa B, Kozyrin I, Low JK, Ferrri V, Vicente E, Prachalias A, Pizanias M, Clift AK, Petrowsky H, Clavien PA, Frilling A. ALPPS in neuroendocrine liver metastases not amenable for conventional resection - lessons learned from an interim analysis of the International ALPPS Registry. HPB (Oxford). 2020;22(4):537–44. doi: 10.1016/j.hpb.2019.08.011.

Zhang XF, Beal EW, Chakedis J, Lv Y, Bagante F, Aldrighetti L, Poultsides GA, Bauer TW, Fields RC, Maithel SK, Marques HP, Weiss M, Pawlik TM. Early recurrence of neuroendocrine liver metastasis after curative hepatectomy: risk factors, prognosis, and treatment. J Gastrointest Surg. 2017;21(11):1821–30. https://doi.org/10.1007/s11605-017-3490-2.

Panzuto F, Nasoni S, Falconi M, Corleto VD, Capurso G, Cassetta S, et al. Prognostic factors and survival in endocrine tumor patients: comparison between gastrointestinal and pancreatic localization. Endocrine-related Cancer. 2005;12(4):1083–92. https://doi.org/10.1677/erc.1.01017.

Article  PubMed  Google Scholar 

Madeira I, Terris B, Voss M, Denys A, Sauvanet A, Flejou JF, Vilgrain V, Belghiti J, Bernades P, Ruszniewski P. Prognostic factors in patients with endocrine tumours of the duodenopancreatic area. Gut. 1998;43(3):422–7. https://doi.org/10.1136/gut.43.3.422.

Tomassetti P, Campana D, Piscitelli L, Casadei R, Santini D, Nori F, Morselli-Labate AM, Pezzilli R, Corinaldesi R. Endocrine pancreatic tumors: factors correlated with survival. Ann Oncol. 2005;16(11):1806–10. https://doi.org/10.1093/annonc/mdi358.

Galleberg RB, Knigge U, Tiensuu Janson E, Vestermark LW, Haugvik SP, Ladekarl M, Langer SW, Grønbæk H, Österlund P, Hjortland GO, Assmus J, Tang L, Perren A, Sorbye H. Results after surgical treatment of liver metastases in patients with high-grade gastroenteropancreatic neuroendocrine carcinomas. Eur J Surg Oncol. 2017;43(9):1682–9.

Clift AK, Hagness M, Lehmann K, Rosen CB, Adam R, Mazzaferro V, Frilling A. Transplantation for metastatic liver disease. J Hepatol. 2023;78(6):1137–1146. https://doi.org/10.1016/j.jhep.2023.03.029. PMID: 37208101.

Fernandes ESM, Kyt CVG, de Mello FPT, Pimentel LS, Andrade RO, Girão C, César C, Siqueira M, Monachesi ME, Brito A, Tavares de Sousa CC, Andraus W, Torres OJM. Liver transplantation in gastroenteropancreatic neuroendocrine tumors. Front Oncol. 2023;12:1001163. https://doi.org/10.3389/fonc.2022.1001163.

D’Amico G, Uso TD, Del Prete L, Hashimoto K, Aucejo FN, Fujiki M, Eghtesad B, Sasaki K, David Kwon CH, Miller CM, Quintini C. Neuroendocrine liver metastases: the role of liver transplantation. Transpl Rev (Orlando). 2021;35(2):100595.

Müller PC, Pfister M, Eshmuminov D, Lehmann K. Liver transplantation versus liver resection for treatment of neuroendocrine liver metastasis: Appraisal of the current evidence. Hepatobiliary Pancreat Dis Int. 2023 Aug 12:S1499-3872(23)00126-1. https://doi.org/10.1016/j.hbpd.2023.08.007. A critical review of liver transplant vs. surgical management for liver metastases in patients with NETs.

• Mazzaferro V, Sposito C, Coppa J, Miceli R, Bhoori S, Bongini M, Camerini T, Milione M, Regalia E, Spreafico C, Gangeri L, Buzzoni R, de Braud FG, De Feo T, Mariani L. The Long-Term Benefit of Liver Transplantation for Hepatic Metastases From Neuroendocrine Tumors. Am J Transplant. 2016;16(10):2892–2902. https://doi.org/10.1111/ajt.13831. A good article summarizing long term outcomes from liver transplantation in NETs from multiple centres.

OPTN/UNOS Liver and Intestinal Organ Transplantation Committee. Briefing Paper: Liver Review Board Guidance Documents. 2017. https://optn.transplant.hrsa.gov/media/2175/liver_boardreport_guidance_201706.pdf. Accessed 21 Jan 2024.

Le Treut YP, Grégoire E, Klempnauer J, Belghiti J, Jouve E, Lerut J, Castaing D, Soubrane O, Boillot O, Mantion G, Homayounfar K, Bustamante M, Azoulay D, Wolf P, Krawczyk M, Pascher A, Suc B, Chiche L, de Urbina JO, Mejzlik V, Pascual M, Lodge JP, Gruttadauria S, Paye F, Pruvot FR, Thorban S, Foss A, Adam R, For ELITA. Liver transplantation for neuroendocrine tumors in Europe-results and trends in patient selection: a 213-case European liver transplant registry study. Ann Surg. 2013;257(5):807 – 15. https://doi.org/10.1097/SLA.0b013e31828ee17c.

Fan ST, Le Treut YP, Mazzaferro V, Burroughs AK, Olausson M, Breitenstein S, Frilling A. Liver transplantation for neuroendocrine tumour liver metastases. HPB (Oxford). 2015;17(1):23–8. https://doi.org/10.1111/hpb.12308.

Moini M, Schilsky ML, Tichy EM. Review on immunosuppression in liver transplantation. World J Hepatol. 2015;7(10):1355–68. https://doi.org/10.4254/wjh.v7.i10.1355.

Yee ML, Tan HH. Use of everolimus in liver transplantation. World J Hepatol. 2017;9(23):990–1000. https://doi.org/10.4254/wjh.v9.i23.990. PMID: 28878864; PMCID: PMC5569278.

Moris D, Tsilimigras DI, Ntanasis-Stathopoulos I, Beal EW, Felekouras E, Vernadakis S, Fung JJ, Pawlik TM. Liver transplantation in patients with liver metastases from neuroendocrine tumors: a systematic review. Surgery. 2017;162(3):525–36. https://doi.org/10.1016/j.surg.2017.05.006.

Austin PC, Xin Yu AY, Vyas MV, Kapral MK. Applying propensity score methods in Clinical Research in Neurology. Neurology. 2021;97(18):856–63. doi: 10.1212/WNL.0000000000012777.

• Maspero M, Rossi RE, Sposito C, Coppa J, Citterio D, Mazzaferro V. Long-term outcomes of resection versus transplantation for neuroendocrine liver metastases meeting the Milan criteria. Am J Transplant. 2022;22(11):2598–2607. doi: 10.1111/ajt.17156. A study comparing outcomes of matched patients who underwent surgical resection vs. liver transplantation. The data suggested better outcomes with liver transplantation, however, some limitation in the study which are described within the manuscript.

Harrelson A, Wang R, Stewart A, Ingram C, Gillis A, Rose JB, El-Rayes B, Azmi A, Chen H. Management of neuroendocrine tumor liver metastases. Am J Surg. 2023;226(5):623–30.

Cazzato RL, Hubelé F, De Marini P, Ouvrard E, Salvadori J, Addeo P, Garnon J, Kurtz JE, Greget M, Mertz L, Goichot B, Gangi A, Imperiale A. Liver-Directed Therapy for Neuroendocrine metastases: from Interventional Radiology to Nuclear Medicine procedures. Cancers (Basel). 2021;13(24):6368. https://doi.org/10.3390/cancers13246368.

Mulier S, Ni Y, Jamart J, Ruers T, Marchal G, Michel L. Local recurrence after hepatic radiofrequency coagulation: multivariate meta-analysis and review of contributing factors. Ann Surg. 2005;242(2):158–71. https://doi.org/10.1097/01.sla.0000171032.99149.fe.

Mazzaglia PJ, Berber E, Milas M, Siperstein AE. Laparoscopic radiofrequency ablation of neuroendocrine liver metastases: a 10-year experience evaluating predictors of survival. Surgery. 2007;142(1):10 – 9. https://doi.org/10.1016/j.surg.2007.01.036.

Berber E, Siperstein A. Local recurrence after laparoscopic radiofrequency ablation of liver tumors: an analysis of 1032 tumors. Ann Surg Oncol. 2008;15(10):2757-64. https://doi.org/10.1245/s10434-008-0043-7.

Henn AR, Levine EA, McNulty W, Zagoria RJ. Percutaneous radiofrequency ablation of hepatic metastases for symptomatic relief of neuroendocrine syndromes. AJR Am J Roentgenol. 2003;181(4):1005-10. https://doi.org/10.2214/ajr.181.4.1811005.

Mohan H, Nicholson P, Winter DC, O’Shea D, O’Toole D, Geoghegan J, Maguire D, Hoti E, Traynor O, Cantwell CP. Radiofrequency ablation for neuroendocrine liver metastases: a systematic review. J Vasc Interv Radiol. 2015;26(7):935–e9421.

Cazzato RL, De Marini P, Leclerc L, Dalili D, Koch G, Rao P, Auloge P, Garnon J, Gangi A. Large nearly spherical ablation zones are achieved with simultaneous multi-antenna microwave ablation applied to treat liver tumours. Eur Radiol. 2020;30(2):971–5. https://doi.org/10.1007/s00330-019-06431-1.

Perrodin S, Lachenmayer A, Maurer M, Kim-Fuchs C, Candinas D, Banz V. Percutaneous stereotactic image-guided microwave ablation for malignant liver lesions. Sci Rep. 2019;9(1):13836.